SPH5030

DRUG2 trials

Sponsors

Shanghai Pharmaceuticals Holding Co., Ltd

Conditions

Advanced Solid TumorBiliary Tract or Colorectal Cancer With Her2-positive/Mutated

Phase 1

A Food Effect Study of SPH5030 Tablets.

CompletedNCT06372223

Shanghai Pharmaceuticals Holding Co., LtdAdvanced Solid Tumor

Start: 2024-03-04End: 2024-03-25Updated: 2024-04-17

Phase 2

A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.

RecruitingNCT06434597

Shanghai Pharmaceuticals Holding Co., LtdBiliary Tract or Colorectal Cancer With Her2-positive/Mutated

Start: 2024-07-17End: 2026-12-31Target: 60Updated: 2025-08-17